FDANews
FDAnews Drug Daily Bulletin

MHRA Guidance Details Risks of Epilepsy Drug During Pregnancy

Feb. 16, 2016

The UK’s Medicines and Healthcare products Regulatory Agency has issued guidance outlining the risks associated with taking epilepsy drug Valproate during pregnancy.

The drug is associated with a risk of birth defects and developmental disorders in children born to women who take valproate during pregnancy.

The agency strengthened labeling last year for the drug, which also is used to treat bipolar disorder and other mental health conditions.